Study to Evaluate the Efficacy, Safety, and Tolerability of Efzofitimod in Patients With Systemic Sclerosis (SSc)-Related Interstitial Lung Disease (ILD) (SSc-ILD)
מצבים רפואיים
Interstitial Lung Disease
סיכום בשפה פשוטהבעזרת בינה מלאכותית
הסיכום נכתב על־ידי מודל שפה והוא ניסיוני. המידע עלול להיות חלקי או שגוי ואינו תחליף לייעוץ רפואי.
מיקומים
aTyr Investigative Site, Los Angeles, California, United States
aTyr Investigative Site, San Diego, California, United States
aTyr Investigative Site, Miami, Florida, United States
aTyr Investigative Site, Chicago, Illinois, United States
aTyr Investigative Site, Chicago, Illinois, United States
aTyr Investigative Site, Chicago, Illinois, United States
aTyr Investigative Site, New Orleans, Louisiana, United States
aTyr Investigative Site, New York, New York, United States
aTyr Investigative Site, Cleveland, Ohio, United States
aTyr Investigative Site, Oklahoma City, Oklahoma, United States
aTyr Investigative Site, Charleston, South Carolina, United States
aTyr Investigative Site, Dallas, Texas, United States
aTyr Investigative Site, Houston, Texas, United States
aTyr Investigative Site, Salt Lake City, Utah, United States
aTyr Investigative Site, Richmond, Virginia, United States
מובילי המחקר
Lisa Carey
Study Director
aTyr Pharma, Inc.